TrialBritish journal of cancer2003

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.

N Verra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.